DermTech (DMTK) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DMTK shares.
View DMTK analyst ratings or view top-rated stocks.

4 brokers have issued twelve-month price targets for DermTech's stock. Their DMTK share price forecasts range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.33 in the next year. This suggests a possible upside of 283.8% from the stock's current price.
View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts.

DermTech's stock was trading at $1.77 at the beginning of the year. Since then, DMTK stock has decreased by 6.8% and is now trading at $1.65.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DMTK earnings forecast.

DermTech, Inc. (NASDAQ:DMTK) announced its earnings results on Thursday, August, 3rd. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.04. The company earned $3.98 million during the quarter, compared to the consensus estimate of $3.55 million. DermTech had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 853.02%.

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

DermTech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.31%), Triatomic Management LP (1.19%), Epiq Partners LLC (0.90%), Geode Capital Management LLC (0.77%), King Luther Capital Management Corp (0.61%) and Woodmont Investment Counsel LLC (0.38%). Insiders that own company stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Ramin Akhavan, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends.

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMTK stock can currently be purchased for approximately $1.65.

DermTech (NASDAQ:DMTK) has a market capitalization of $55.61 million and generates $14.52 million in revenue each year. The company earns $-116,680,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

The company employs 278 workers across the globe.

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.